Drug intelligence / Profile preview

Ping Chuan Ke Li + montelukast

Development stage: Unknown
Lead developer: Heilongjiang University of Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Ping Chuan Ke Li + montelukast is a combination therapy that pairs a traditional Chinese medicine formulation (Ping Chuan Ke Li) with a conventional leukotriene receptor antagonist (montelukast). This combination has been studied for its efficacy in treating chronic asthma, with clinical trials showing improved lung function and quality of life compared to montelukast alone in some studies. Montelukast works by blocking the cysteinyl leukotriene receptor 1 (CysLTR1), which helps reduce inflammation in the airways.

Other names: PCKL + montelukast

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)

Beyond the preview

Go deeper on Ping Chuan Ke Li + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ping Chuan Ke Li + montelukast.

Explore the full profile